Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824901 · ClinicalTrials.gov registry record · Phase 1
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01824901 is a Phase 1 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 2 participants.
The verdict
NCT01824901, a Phase 1 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This randomized phase I/II trial studies the side effects and best dose of fibroblast growth factor receptor (FGFR) inhibitor AZD4547 when given with docetaxel and to see how well it works in treating patients with recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FGFR inhibitor AZD4547 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether docetaxel and FGFR inhibitor AZD4547 are more effective when given together or separately.
Interventions
- DRUG docetaxel
- DRUG AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-01-15 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824901
The ClinicalTrials.gov registry entry for NCT01824901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT01824901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01824901 about?
NCT01824901 is a clinical study titled "Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer". This randomized phase I/II trial studies the side effects and best dose of fibroblast growth factor receptor (FGFR) inhibitor AZD4547 when given with docetaxel and to see how well it works in treating patients with recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, ...
What is the current status of trial NCT01824901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-01-15. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01824901?
The interventions under investigation include: docetaxel (DRUG), AZD4547 (DRUG).
Who is sponsoring clinical trial NCT01824901?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.